- 48North branded pod: 48North's recognizable, market-leading, and beloved brand; single stain, ultra-refined and purified cartridge filled with cannabis from 48North's indoor, craft facility delshen
- Trail Mix branded pod: an accessibly priced cartridge filled with cannabis from 48North's outdoor, natural production facility, Good:Farm
Wednesday, 1 April 2020
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 393 (CSE: $EASY.C), (TSXV: $N.V) (OTC: $NXTTF), (TSXV: $NRTH.V)
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 393 (CSE: $EASY.C), (TSXV: $N.V) (OTC: $NXTTF), (TSXV: $NRTH.V)
Delta, Kelowna, BC, April 1, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/04011EASY-N-NXTTF-NRTH.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we are looking at a few public announcements.
Neuraxpharm, a leading European specialty pharmaceutical company, together with Panaxia Labs Israel (TASE: PNAX), Israel's largest medical cannabis manufacturer, today announced it is starting to market medical cannabis products, becoming the first European pharmaceutical company to include medical cannabis products in its portfolio. Neuraxpharm, which specializes in pharmaceutical products for the central nervous system (CNS), chose Panaxia Labs Israel, Israel's largest medical cannabis manufacturer, as its partner in a business collaboration for the manufacture, commercialization and distribution of advanced medical cannabis products in Germany, Europe's largest and fastest-growing medical cannabis market.
The breakthrough agreement inked by the two companies positions them as dominant players in the international cannabis market. The agreement is expected to cover more markets in the future. To date, collaborations between large pharmaceutical and medical cannabis companies were limited to research and development partnerships or local-scale distribution. The establishment of the business collaboration reflects Neuraxpharm's and Panaxia's strategy to become a European leader in the commercialization of medical cannabis products.
Currently, a complex patchwork and different regulatory approaches for cannabis use are found across the European countries. While the sector is still in its early stages, market possibilities are expected to increase strongly with the growing acceptance of medical cannabis in more countries.
With its direct presence in now 12 European countries and annual revenues of around EUR 480 million, Neuraxpharm is a leading European CNS Specialist. Neuraxpharm covers over 80% of the European CNS drug market with its pharmaceutical products with more than 130 different CNS active ingredients.
With over 60,000 patients treated with medical cannabis (out of a total population of 82.8 million), Germany is the largest medical cannabis market outside the USA. The average cannabis expenditure per patient in Germany is EUR500 per month. The market is backed by regulatory support, concurrently with strict quality standards and increasing demand for advanced administration methods. With the consistent increase in the number of patients treated with medical cannabis, the market is expected to account for 1-2% of Germany's population in four years. Products are prepared and sold prescription only by specially certified pharmacies.
Initial sales in Germany of the Panaxia / Neuraxpharm medical cannabis products are expected upon the receipt of the regulatory approval later in 2020.
SpeakEasy Cannabis Club Ltd. (CSE: EASY), a holder of a federal licence to cultivate, process and sell cannabis under the Cannabis Act, announced that it has signed a non-binding letter of intent with Christina Lake Cannabis Corp.
The LOI contemplates that CLC will contract SpeakEasy to process and sell cannabis biomass and cannabis flower produced at their CLC production facility and SpeakEasy intends to provide, upon receipt of the appropriate licences, processing of biomass and flower, sales and distribution of the flowers and work jointly with CLC to develop and produce white label, value added products made from CLC input material.
Contract processing for CLC will make use of SpeakEasy's process facility to become an additional revenue stream. The additional material is expected to aid in SpeakEasy's ability to keep up to expected domestic and international markets.
Climatic region, genetics and growing techniques of CLC, being similar to SpeakEasy's methods, allows for easy cooperation and sharing of supplies, equipment and technology between the two companies. Growers on both farms have vast experience, therefore it is expected that the finished product will be comparable and will market well together. Founder Marc Geen states, "I'm thrilled to be working with the team from Christina Lake Cannabis, we've known each other for years and I couldn't be happier to have our two families cooperating together."
SpeakEasy anticipates that it will have a strong effect on the market with the cost of its flower produced outdoors being comparatively lower than the industry average. Having additional supply of extremely competitively priced material will allow us to enter more supply agreements with Province's across Canada.
SpeakEasy is working with and supporting local growers and producers both large and small here in BC with a goal of promoting "BC Bud" as a globally recognized brand. Founder, Marc Geen states, "Working with other like-minded growers towards a common goal is extremely exciting, it happens in all other forms of farming for very good reason. We have so many advantages growing in BC, working with fellow farmers can compound those advantages."
Namaste Technologies Inc. (TSXV: N) (OTC: NXTTF), a leading online platform for cannabis products, accessories, and responsible education, today provided an update with respect to the impact from the COVID-19 virus outbreak on its current operations.
On March 23, 2020 the Ontario government announced non-essential services must close their doors due to the COVID-19 pandemic, however certain sectors of the economy including liquor and cannabis retail and wholesale operations have been deemed essential services and are permitted to operate. Other provincial governments have followed Ontario's lead and many online and retail cannabis stores remain open across Canada. Namaste's wholly owned subsidiary, CannMart Inc. ("CannMart") plays an important role within the Canadian cannabis supply chain and is committed to remain open to serve its online patients and B2B customers including provincial government stores. Where possible employees are working from home and others are adhering to strict operating procedures to safeguard the health and safety of staff to ensure operations remain unaffected. To date, there have been no known cases of COVID-19 at any of Namaste offices or facilities and there have been no operational disruptions.
"In these extraordinary times, our thoughts go out to those working the frontlines and those who have been touched by the coronavirus," said Meni Morim, CEO of Namaste Technologies. "The health and safety of our people, patients and customers, business partners, investors and their communities are our top priority. We will continue to monitor the progress of COVID-19 developments and will act accordingly for the health and safety of all stakeholders."
Namaste also announced that its continuing effort to strengthen its business model with the addition of Adastra Labs to the Namaste and CannMart family. CannMart Labs Inc. has entered into an agreement with Adastra Labs Holdings Ltd. (CSE: XTRX) to supply cannabis extract and concentrate products. Adastra is a provider of same-site Health Canada licensed cannabis extraction and analytical testing services. The agreement provides for supply of cannabis extract and concentrates for Namaste's family of products available through CannMart.com and Namaste's network of government cannabis stores. Under the terms of the agreement, Adastra will supply standard processing services to CannMart Labs for cannabis extract and concentrate products over a period of 12 months expected to begin on May 1st, 2020.
According to a recent article in the Marijuana Business Daily industry sources say cannabis stores in Ontario and Alberta have reported unprecedented demand due in part to the COVID-19 outbreak. Namaste is committed to managing the recent surge in demand by keeping the supply lines open to its patients and customers while continuing to focus on employee and customer health. The Company has been successful at adding additional cannabis brands and products to CannMart's product line. Adastra Labs is a part of Namaste's increase in focus on profitable business relationships as it navigates the new realities facing the cannabis industry.
As previously announced in January, CannMart submitted notification for several new product SKUs including edible cannabis products, which are being manufactured by Choklat Inc, a company that Namaste holds a 49% equity interest in. These products are to be formulated, developed and packaged to meet the regulatory requirements as set out by Health Canada. While the Company expected to make these new products available in March, delays in packaging materials has caused the Company to defer its delivery schedule at this time.
Fume Labs, and 48North Cannabis Corp. (TSXV: NRTH) announced today that it signed a supply agreement with PAX Labs (Canada) Inc.
Under the terms of the agreement, Fume Labs will develop cannabis oil pods for the PAX Era.
The PAX Era, an award-winning vaporizer system for cannabis concentrates, will provide consumers with a superior cannabis experience, delivering quality, control and predictability to each session. PAX is a market leader in vaporization technology, with nearly 1.5 million Era devices sold and an established reputation as the best-selling pen-and-pod system in the United States.
The agreement between PAX Labs – an industry-leading brand, well-known for premium quality and consistency – and Fume Labs is a testament to Fume Labs' operational expertise in the production of cannabis products, specializing in concentrate extraction and refining, formulation and filling, and packaging and distribution.
At launch, Fume Labs will manufacture two cannabis oil pods for the PAX Era:
Importantly, Fume Labs' Chief Science Officer, Talaal Rshaidat has significant experience
filling PAX Era pods in the United States, most recently with Liberty Health Sciences, where he was responsible for extraction and product development. Talaal's experience is invaluable to Fume Labs and well positions the strategic partnership to successfully deliver on this agreement with Pax Labs.
In the near term, Fume Labs looks forward to announcing additional partnerships, with other Licensed Producers and cannabis brands.
Fume Labs, the cannabis-focused manufacturing and extraction entity operates out of
48North's fully-licensed processing and propagation facility "Good:House," located in Brantford, ON.
48North is the party responsible for manufacturing, packaging, marketing, and promoting, and selling products from Fume Labs under the authority of its cannabis licenses.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
800 665 0411
Investor Ideas #Potcasts 562, #Cannabis News and #Stocks on the Move; (CSE: $XTRX.C), (NASDAQ: $VFF) (TSX: $VFF.TO), (CSE: $TRUL.C) (OTC: $TCNNF
Investor Ideas #Potcasts 562, #Cannabis News and #Stocks on the Move; (CSE: $XTRX.C), (NASDAQ: $VFF) (TSX: $VFF.TO), (CSE: $TRUL.C...
Investorideas.com - Cannabis Stock News: TransCanna (CSE: TCAN) Product Ranks in Leafly's Top Cannabis Strains ListInvestorideas.com - Cannabis Stock News: TransCanna (CSE: TCAN) Product Ranks in Leafly's Top Cannabis Strains List
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Aurora Cannabis (TSX: $ACB.TO) (NYSE: $ACB), Khiron Life Sciences (TSXV: $KHRN.V), (OTCQB: $KHRNF), Cannabis One Holdings (CSE: $CBIS.C), Liht Cannabis (CSE: $LIHT.C) and FSD Pharma (CSE: $HUGE.C) (OTCQB: $FSDDF)Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Aurora Cannabis (TSX: $ACB.TO) (NYSE: $ACB), Khiron Life Sciences (TSXV:...
Investorideas.com - #Cannabisstocks: Rapid Dose Therapeutics (CSE: DOSE) and Thrive Cannabis Sign MOU to Provide Quickstrip(TM) Oral Thin Strips Under a White Label Manufacturing AgreementInvestorideas.com - #Cannabisstocks: Rapid Dose Therapeutics (CSE: DOSE) and Thrive Cannabis Sign MOU to Provide Quickstrip(TM) Oral Thin St...